Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Cancer research·2026
Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

SMPD3 suppresses oligodendroglioma growth via dual autocrine-paracrine roles.

Communications biology·2026
Same author

International Delphi-based Consensus: Therapeutic Approaches for Pediatric Adrenocortical Carcinoma.

European journal of endocrinology·2026
Same author

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Nature communications·2026

Related Experiment Video

Updated: Sep 16, 2025

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

11.7K

Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy.

Nadine Azzam1, Jamie I Fletcher2,3, Nicole Melong1

  • 1Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.

Cancer Research Communications
|July 10, 2025
PubMed
Summary
This summary is machine-generated.

Larval zebrafish patient-derived xenografts (PDXs) rapidly and accurately predict pediatric cancer drug responses. This approach offers a faster, more cost-effective alternative to mouse PDXs for precision oncology.

More Related Videos

Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

2.9K
Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis
12:08

Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis

Published on: June 19, 2021

12.5K

Related Experiment Videos

Last Updated: Sep 16, 2025

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

11.7K
Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

2.9K
Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis
12:08

Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis

Published on: June 19, 2021

12.5K

Area of Science:

  • Pediatric Oncology
  • Translational Medicine
  • Xenograft Models

Background:

  • 30% of high-risk pediatric cancers lack actionable molecular targets, limiting treatment options.
  • Mouse patient-derived xenograft (PDX) models show promise but face challenges in timely clinical application.
  • There is a critical need for rapid and reliable drug response prediction in pediatric precision oncology.

Purpose of the Study:

  • To demonstrate the proof-of-principle for using individualized larval zebrafish PDX models to rapidly assess clinical drug responses in high-risk pediatric cancers.
  • To compare the efficacy of zebrafish PDX models against conventional mouse PDX models in predicting patient outcomes.
  • To evaluate the potential of zebrafish PDXs for real-time, clinically relevant drug response data generation.

Main Methods:

  • Retrospective analysis of tumor samples from 10 pediatric patients with high-risk cancers.
  • Establishment and drug response testing of larval zebrafish PDX models.
  • Correlation of zebrafish PDX drug responses with patient clinical responses and comparison with mouse PDX models.
  • Assessment of responses to single-agent and combination therapies.

Main Results:

  • Zebrafish PDXs were successfully established from all 10 patients, yielding robust drug response data in every case.
  • Zebrafish models provided data for three patients whose tumors failed to engraft in mice.
  • Zebrafish PDX models accurately recapitulated patient responses for 11 out of 12 treatment regimens tested.
  • High concordance was observed between zebrafish PDX, mouse PDX, and patient outcomes.

Conclusions:

  • Individualized larval zebrafish PDX models offer a robust, rapid, and cost-effective platform for predicting drug responses in high-risk pediatric cancers.
  • Zebrafish PDX models demonstrate significant potential for improving precision medicine strategies in pediatric oncology.
  • These findings support the prospective use of zebrafish PDX models to guide clinical treatment decisions in real-time.